Company Overview and News

to your dashboard

Headline News

Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock

2017-11-14 zacks
Investors in Infinity Pharmaceuticals, Inc. (INFI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17th 2017 $3.00 Call had some of the highest implied volatility of all equity options today. (97-3)

Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity"), following which we have published a free report that can be viewed by signing up at The Company announced on November 10, 2017, Phase-1 clinical and translational data for IPI-549, its oral immuno-oncology development candidate. (84-0)

Infinity Pharmaceuticals: When Safety Is A Win

2017-11-10 seekingalpha
Readers should pay attention to the safety and tolerability of IPI-549, not response rates in the monotherapy portion of the study. (141-1)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

ROTY Edition 1 Volume 48: Cutting A Position Loose And Promising Updates On Current Holdings

2017-11-08 seekingalpha
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)

Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

2017-11-08 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 14 cents per share in third-quarter 2017, narrower than the Zacks Consensus Estimate of a loss of  21 cents. The company had reported a loss of 39 cents in the year-ago quarter. (215-0)

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company’s Financial Results for the Third Quarter of 2017. My name is Glenda and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Infinity’s request. (141-0)

ROTY Volume 1 Edition 47: Understanding Mr. Market's Temper Tantrums And Updates

2017-11-07 seekingalpha
I touch on the importance of distinguishing between true high volume institutional selling and momentary temper tantrums thrown by Mr. Market. (98-0)

BRIEF-Infinity Q3 loss per share $0.14

2017-11-07 reuters
* Infinity Pharmaceuticals Inc - ‍infinity expects net loss for 2017 to range from $40 million to $50 million​ (69-0)

ROTY Volume 1 Edition 44: Global Blood Therapeutics In Focus And Other Catalysts

2017-10-31 seekingalpha
I highlight Global Blood Therapeutics and recent results from the case study as indicative of further upside ahead. (110-4)

Top Biopharma Events Coming by the End of 2017

2017-10-28 247wallst
As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector as it’s been one of the best performing this year, second to technology, in the S&P 500. (374-16)

ROTY Volume 1 Edition 42: Thoughts On Underpeformers And New Trades

2017-10-24 seekingalpha
We are also swapping a Contender for a current ROTY holding due to higher perceived upside and an important near term catalyst. (132-6)

Infinity, Wells Fargo Upgrade, SITC Meeting in November, IPI-549 Update

2017-10-23 accesswire
NEW YORK, NY / ACCESSWIRE / October 23, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. (169-3)

ROTY Volume 1 Edition 40: More Exciting Updates And Trades

2017-10-17 seekingalpha
I give a brief overview of predictive and reactive trading, noting how we incorporate both in ROTY. (352-7)

Top Business News of the Week: AT&T, NVIDIA, MannKind, PG&E, Walmart and Many More

2017-10-14 247wallst
The Dow and S&P 500 are at all-time highs, and the bull market is now closer to nine years old than eight. Even though the indexes are all well above 200% from their 2009 lows, the reality is that it is not a bull market everywhere. There are also a lot of news items outside of earnings that have to be considered by equity investors. (216-1)

Stock Research Report

Infinity Pharmaceuticals is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity Pharmaceuticals is focusing its efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.

Preclinical research has demonstrated that PI3K-gamma is highly expressed in tumor-associated macrophages and that blockade of PI3K-gamma signaling by treatment with IPI-549 results in a reprogramming of macrophages in the tumor microenvironment from the M2, or pro-tumor, phenotype to the M1, or anti-tumor, phenotype. This shift increased the number and activity of anti-tumor T cells that can attack the tumor and also increased the production of pro-inflammatory cytokines, which can further stimulate an anti-tumor immune response. Preclinical data from multiple solid tumor models demonstrated that IPI-549 was active as a monothe...

Click for full article
CUSIP: 45665G303